AR and benign prostatic hyperplasia: Concerning the potential treatment for androgen-regulated diseases like benign prostatic hyperplasia and prostate cancer, several natural compounds have been recognized as agonists or antagonists against androgens [10–15], and display the tissue-selective activation of androgenic signaling [16], which are so called selective androgen receptor modulators (SARMs) by competitively binding to androgen receptor (AR).